Company Overview and News
Mumbai: Shares of Tata Consultancy Services Ltd (TCS) gained 2.8% in morning trade on Wednesday after the company said its board of directors will meet on 15 June to consider share buyback.
WIT 532540 PUK.PRA PUK PUK.PR INFY TCS TTNQY PUKPF
Bengaluru: Tata Consultancy Services Ltd (TCS) expects to generate $1.36 billion in revenue over 10 years from its partnership with a unit of British insurer Prudential Plc.
INFY TCHQY TTNQY 532755 TECHM WIT 532540 PUK.PRA PUK PUK.PR TCS AGN PUKPF
NEW YORK (Reuters) - U.S. insurer Lincoln National Corp could deliver shareholder returns of 20 percent or more in the coming year, as the market for the company’s main product, variable annuities, recovers, Barron’s reported.
LNC PUK.PRA PUK PUK.PR LNC.WS PUKPF
First Majestic Silver Corp. (NYSE:AG) has 151 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 69,255,077 shares. Largest shareholders include Wheaton Precious Metals Corp., Van Eck Associates Corp, Morgan Stanley, Vanguard Group Inc, Global X Management CO LLC, Credit Suisse Ag/, Prudential Plc, Connor, Clark & Lunn Investment Management Ltd.
WPM FR MS.PRE MS.PRF MS.PRG MS.PRA PUK.PRA MS.PRI PUK MS.PRK PUK.PR AG MS PUKPF
Last week, Barclays (BCS - Free Report) acquired £4.3 billion ($5.8 billion) worth of Irish residential mortgage loans from Lloyds Banking Group (LYG - Free Report) . The portfolio comprises around 27,000 mortgages, originated between 2004 and 2010. Of the total loans acquired, nearly £300 million are impaired. Mortgage loan portfolio incurred a pre-tax loss of roughly £40 million in 2017. Notably, Lloyds is expected to record £110 million in pre-tax loss on the deal in second-quarter 2018.
WFCNP WFC.PRL WFC.PRJ PRU WFC.PRT WFC.PRR PUK.PRA WFC.PRQ WFC.PRP LLOBF WFC.PRO PUK WFC.PRN 8306 WFC.PRY WFC.PRX MBFJF WFC.PRW CSIQ WFC.PRV PUKPF WFC WFC.WS LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLPG PUK.PR MUFG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 MTU LLD2
6-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to PUK / Prudential PLC on message board site Silicon Investor.
|frenchmen i admire the most|
as of ET